Castle Biosciences' AdvanceAD-Tx Test Honored with 2026 MedTech Breakthrough Award for Innovation
Castle Biosciences, Inc., a prominent player in the health diagnostics sector, has achieved an impressive milestone by winning the coveted 2026 MedTech Breakthrough Award for its AdvanceAD-Tx™ test. This recognition underscores Castle's commitment to enhancing patient care through groundbreaking testing solutions. The AdvanceAD-Tx test has been specifically designed for patients aged 12 and older who suffer from moderate-to-severe atopic dermatitis (AD), a skin condition that affects millions globally.
This award marks Castle's fifth recognition at the MedTech Breakthrough Awards, which celebrate innovations that significantly improve patient care within the healthcare and medical technology landscape. Notably, the AdvanceAD-Tx test earned the title of "Genomics Innovation Award" during the tenth annual program, highlighting its role in driving meaningful progress in the industry.
According to Castle's president and CEO, Derek Maetzold, the AdvanceAD-Tx test builds upon the company's longstanding expertise in dermatology and gene expression profiling. By applying a clinically validated gene expression profile (GEP), the test aims to facilitate more informed systemic treatment decisions. This is particularly vital for patients dealing with the complexities of atopic dermatitis, as the disease can be biologically heterogeneous, often making treatment decisions challenging for clinicians.
The AdvanceAD-Tx test employs a novel, non-invasive methodology that analyzes lesional skin scraping samples, eliminating the need for biopsies. It evaluates the expression of 487 genes related to 12 inflammatory pathways associated with AD. The analytical results categorize patients into two distinct profiles: a Janus kinase (JAK) Inhibitor Responder Profile or a T-helper 2 (Th2) Molecular Profile. This classification allows for more personalized therapy matching based on an individual’s immune profile using objective molecular insights, potentially reducing the cycle of ineffective treatments.
In clinical validation studies, patients designated with a JAK Inhibitor Responder Profile, and treated correspondingly, demonstrated remarkable outcomes. They were 5.5 times more likely to achieve near-clear skin (EASI-90) compared to those treated with a Th2-targeted therapy, and they reached that response 3.8 times faster. Furthermore, these patients enjoyed enhanced quality of life with significantly less itchiness and fewer flare-ups, all without the need for dosage escalation.
Steve Johansson, managing director at MedTech Breakthrough, articulated the profound implications of the AdvanceAD-Tx test. He emphasized that traditional treatment selection for atopic dermatitis has relied heavily on clinical assessments, which often overlook the underlying biological factors driving the disease. The innovative test provides an objective understanding of disease biology and enhances treatment selection for systematic therapies, thus transforming the management landscape for moderate-to-severe AD.
Castle's recognition at the MedTech Breakthrough Awards is not new; the company has previously earned accolades for other pioneering tests, including the "Best Use of Artificial Intelligence in Healthcare" for the TissueCypher® Barrett's Esophagus test in 2023, and various rewards for its DecisionDx® product line. This year’s MedTech Breakthrough program witnessed an unprecedented influx of nominations from over 20 countries, highlighting the growing significance and impact of digital healthcare innovations worldwide.
In summary, Castle Biosciences' AdvanceAD-Tx test stands as a testimony to how advanced molecular testing can pave the way for personalized, effective treatment options for patients battling atopic dermatitis. As the healthcare industry continues to evolve, solutions like AdvanceAD-Tx are vital for improving the quality of patient care and outcomes.
For more detailed insights into the AdvanceAD-Tx test and Castle Biosciences' mission, visit their official site at Castle Biosciences.
This award marks Castle's fifth recognition at the MedTech Breakthrough Awards, which celebrate innovations that significantly improve patient care within the healthcare and medical technology landscape. Notably, the AdvanceAD-Tx test earned the title of "Genomics Innovation Award" during the tenth annual program, highlighting its role in driving meaningful progress in the industry.
According to Castle's president and CEO, Derek Maetzold, the AdvanceAD-Tx test builds upon the company's longstanding expertise in dermatology and gene expression profiling. By applying a clinically validated gene expression profile (GEP), the test aims to facilitate more informed systemic treatment decisions. This is particularly vital for patients dealing with the complexities of atopic dermatitis, as the disease can be biologically heterogeneous, often making treatment decisions challenging for clinicians.
The AdvanceAD-Tx test employs a novel, non-invasive methodology that analyzes lesional skin scraping samples, eliminating the need for biopsies. It evaluates the expression of 487 genes related to 12 inflammatory pathways associated with AD. The analytical results categorize patients into two distinct profiles: a Janus kinase (JAK) Inhibitor Responder Profile or a T-helper 2 (Th2) Molecular Profile. This classification allows for more personalized therapy matching based on an individual’s immune profile using objective molecular insights, potentially reducing the cycle of ineffective treatments.
In clinical validation studies, patients designated with a JAK Inhibitor Responder Profile, and treated correspondingly, demonstrated remarkable outcomes. They were 5.5 times more likely to achieve near-clear skin (EASI-90) compared to those treated with a Th2-targeted therapy, and they reached that response 3.8 times faster. Furthermore, these patients enjoyed enhanced quality of life with significantly less itchiness and fewer flare-ups, all without the need for dosage escalation.
Steve Johansson, managing director at MedTech Breakthrough, articulated the profound implications of the AdvanceAD-Tx test. He emphasized that traditional treatment selection for atopic dermatitis has relied heavily on clinical assessments, which often overlook the underlying biological factors driving the disease. The innovative test provides an objective understanding of disease biology and enhances treatment selection for systematic therapies, thus transforming the management landscape for moderate-to-severe AD.
Castle's recognition at the MedTech Breakthrough Awards is not new; the company has previously earned accolades for other pioneering tests, including the "Best Use of Artificial Intelligence in Healthcare" for the TissueCypher® Barrett's Esophagus test in 2023, and various rewards for its DecisionDx® product line. This year’s MedTech Breakthrough program witnessed an unprecedented influx of nominations from over 20 countries, highlighting the growing significance and impact of digital healthcare innovations worldwide.
In summary, Castle Biosciences' AdvanceAD-Tx test stands as a testimony to how advanced molecular testing can pave the way for personalized, effective treatment options for patients battling atopic dermatitis. As the healthcare industry continues to evolve, solutions like AdvanceAD-Tx are vital for improving the quality of patient care and outcomes.
For more detailed insights into the AdvanceAD-Tx test and Castle Biosciences' mission, visit their official site at Castle Biosciences.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.